Multicomponent Plasmid Protects Mice From Spontaneous Autoimmune Diabetes

Area of Science:

• Immunology
• Endocrinology
• Gene Therapy

Background:

• Type 1 diabetes (T1D) is an autoimmune disease destroying insulin-producing beta cells, necessitating lifelong insulin therapy.
• Current T1D treatments lack disease-modifying options, and future immunotherapies must avoid broad immune suppression.

Purpose of the Study:

• To evaluate a novel plasmid-based immunotherapy for preventing autoimmune diabetes.
• To assess antigen-specific tolerization and immune modulation in a preclinical model.

Main Methods:

• Development of a plasmid encoding preproinsulin2 and immune-modulatory cytokines (transforming growth factor-beta-1, interleukin-10, interleukin-2).
• Administration via intramuscular or subcutaneous injection in non-obese diabetic mice.
• Analysis of diabetes prevention, immune cell modulation, and cytokine profiles.

Main Results:

• Near-complete prevention of autoimmune diabetes was achieved in mice.
• Efficacy was dependent on both preproinsulin2 and the cytokine combination, indicating antigen-specific tolerization.
• Intramuscular treatment increased endogenous IL-10 and modulated myeloid cells without global immunosuppression.

Conclusions:

• This multi-component, plasmid-based immunotherapy holds potential for inducing self-tolerance in individuals at risk for T1D.
• The study identified relevant cytokine and immune cell biomarkers for future clinical trials.
• A modified plasmid for clinical use demonstrated comparable efficacy and is currently in Phase 1 trials.